This document provides a summary of the background and qualifications of Martin C. Michel, MD, MAE, FBPhS. He has over 30 years of experience in clinical research, experimental research, and their integration in both academia and industry. Key areas of expertise include urogenital and cardiovascular medicine. He has held senior leadership roles at universities and large pharmaceutical companies. He has authored over 500 publications that have been cited over 20,000 times and has an h-index of 73. He is recognized as a leader in his field and has received numerous honors and awards for his contributions to pharmacology research.

1. Martin C. Michel, MD, MAE, FBPhS
Current location: Mainz, Germany
Key competencies
- Physician/researcher with >30 years of experience in experimental research, clinical
research and their integration in academia and industry.
o Board certification in clinical pharmacology.
- Experience in broad range of therapeutic areas.
o Primarily urogenital and cardiovascular medicine, but also CNS, respiratory,
metabolism and oncology.
- Inspirational speaker and effective communicator.
o Regularly invited by learned societies and academic institutions and in
industry-sponsored events.
Key experiences
- Senior Director and Head of Global Product & Pipeline Scientific Support, Boehringer
Ingelheim 2011-2016
o Responsible for all internal and external non-clinical research on compounds in
late-stage development and on the market. This applied to all therapeutic areas
of the company (cardiovascular, metabolism, respiratory, CNS and oncology)
and included relationship management with internationally leading external
experts. A key task was the development of translational research strategies
(including publication strategies) and processes for each product and their
alignment with various internal stakeholders including Medicine and
Marketing.
- Highly successful career in academia
o Head of Department of Pharmacology & Pharmacotherapy, University of
Amsterdam, Netherlands 2003-2011
o Head Research and Diagnostic Laboratories Nephrology & Hypertension,
University of Essen, Germany 1993-2002
o More than 500 publications cited more than 20,000 times; h-index 73
- Work experiences in four countries and fluency in their local languages
o US, Germany, Austria, Netherlands
Key successes
- Leadership role in development of blockbuster drug (tamsulosin/Flomax®
): discovery
of mechanism of action, translational pharmacology program, clinical development,
phase IV studies and OTC development as documented in 12 experimental and 12
clinical studies as lead investigator
- Responsible for development plan for overactive bladder drugs for one large
(Boehringer Ingelheim) and one small company (Elbion)
o Key external adviser for such programs for two other companies (Astellas and
Schwarz Pharma, later acquired by Pfizer)
o Development of translational research strategy for one of these programs
(Astellas)
- Recognition as peer by leading academic and clinical experts

2. Education
1987-1989 Postdoctoral fellow University of California San Diego (Mentor Paul A. Insel).
Molecular pharmacology research on α1- and β-adrenoceptors and neuropeptide Y receptor
with focus on cardiovascular system.
1985-1987 Postdoctoral fellow University of Essen Medical School (Mentor Otto-Erich
Brodde). α1-, α2- and β-adrenoceptor receptor research with focus on hypertension and
heart failure.
1978-1985 Medical School at University of Essen (Germany) and University of Vienna
(Austria); doctoral thesis in biochemistry (Supervisor Rüdiger Ghraf)
Work experience
2016-present Senior Partner PAASP, Heidelberg, Germany. Consultancy specializing on
quality and robustness of preclinical data. Responsible for strategy development and
networking.
2012-present Professor of Pharmacology, Johannes Gutenberg University, Mainz,
Germany. Urogenital and cardiovascular research, particularly β3-adrenoceptors and
angiotensin receptors.
2011-2016 Global Head Product & Pipeline Scientific Support, Boehringer Ingelheim.
Global responsibility for all non-clinical research related to compounds in late-stage
development or on the market and across all therapeutic areas including cardiovascular,
diabetes, respiratory, oncology and CNS.
2003-2011 Professor and Head Dept. of Pharmacology and Pharmacotherapy,
University of Amsterdam, Netherlands. Urogenital and cardiovascular research, particularly
muscarinic receptors, β3-adrenoceptors and sphingolipids.
1996-2002 Professor of Pharmacology, University of Essen, Germany. Cardiovascular and
urogenital research, particularly muscarinic receptors, α1-adrenoceptors and sphingolipids.
1993-2002 Head Nephrology Research Labs, Dept. of Medicine, University of Essen
Medical School. Responsible for catecholamine and renin/aldosterone diagnostics,
therapeutic drug monitoring for immunosuppressants and clinical pharmacology consults.
Research on α1- and α2-adrenoceptor and neuropeptide Y receptor with focus on
cardiovascular and renal disease.
1998-1999 Professor and Acting Head Dept. of Pharmacology and Toxicology, Ruhr-
University Bochum Medical School, Bochum, Germany.
1991-1997 Assistant Adjunct Professor of Pharmacology, University of California San
Diego, USA. α1-, α2- and β-adrenoceptor and neuropeptide Y receptor research with focus on
cardiovascular system.
1989-1993 Senior researcher in the Nephrology Research Labs, Dept. of Medicine,
University of Essen Medical School. α1-, α2- and β-adrenoceptor and neuropeptide Y
receptor research with focus on cardiovascular system.
Continuous research funding from public (German government, European Union) and
private sources (Astellas, Boehringer Ingelheim, Pfizer, Theravance, Velicept Therapeutics).
Publications (key publications listed at end)
300 original articles
9 patents
82 review articles
13 letters to the editor and case reports
10 peer-reviewed internet publications
36 book chapters and monographs
50 published lectures (proceedings papers)

3. 110 other peer-reviewed publications
>20,000 total citations to these publications, resulting in an h-index of 73 (Google Scholar)
Honors and awards
1987 President’s award for best doctoral thesis, University of Essen
1989 Award for Trainees in Clinical Research, American Federation of Clinical Research
1990 Walter-Clawiter award for hypertension research, University of Düsseldorf (shared with
O.-E. Brodde)
1998 Maximilian-Nitze award German Society of Urology (shared with M. Goepel, U.
Hecker, S. Krege und H. Rübben)
2008 Elected member Academia Europaea (European Academy of Sciences)
2011 Reviewer of the Year of The Journal of Urology
2012 Reviewer of the Year of The Journal of Urology
2012 Elected Fellow British Pharmacological Society
2014 Best Reviewer of International Journal of Urology
2014 Invited plenary lecture World Congress of Pharmacology
2015 Invited plenary opening lecture Australian Society for Clinical and Experimental
Pharmacology and Australasian Pharmaceutical Sciences Association
Professional organization appointments
1996-2013 member and chair IUPHAR nomenclature committee on neuropeptide Y/peptide
YY/pancreatic polypeptide receptors
1997-2011 member of WHO expert panel ”α-blocker treatment of BPH”
2004-2011 member German Society of Urology guideline panel “Diagnostics and treatment
of BPH”
2006-2011 member European Association of Urology guideline panel “Male voiding
dysfunction”
2007-2011 member International Consultation of Incontinence guideline panel “Medical
treatment of incontinence”
2012-present member and chair IUPHAR nomenclature committee on β3-adrenoceptors
2016-present member and chair IUPHAR committee on best practice of study design and data
analysis
Editorships
1999-2002 Associate Editor Naunyn-Schmiedeberg’s Archives of Pharmacology
2002-2016 Editor-in-chief Naunyn-Schmiedeberg’s Archives of Pharmacology
2016-present Associate Editor Naunyn-Schmiedeberg’s Archives of Pharmacology
1998-2003 British Journal of Pharmacology, editor
2005-2010 XPharm (pharmacological online database), editor
2007-present Handbook of Experimental Pharmacology, series editor
2009-present Pharmacological Reviews, associate editor
2010-present associate editor Frontiers in Pharmacology Analytical and Experimental
Pharmacology section
2010-2011 Frontiers in Pharmacology editor-in-chief Urogenital Disease section
2011-present Frontiers in Pharmacology editor-in-chief Cardiovascular and Smooth Muscle
Pharmacology section
Editorial board memberships
1994-1998 Naunyn-Schmiedeberg’s Archives of Pharmacology
1996-2000 Journal of Clinical Investigation
2002-present Basic Research in Cardiology

4. 2002-present Molecular Pharmacology
2002-2011 Urologe
2004-present International Journal of Pharmacology
2005-2011 Current Drug Safety
2006-present European Urology
2006-present American Journal of Physiology (Cell Physiology)
2007-2009 Journal of Hypertension
2008-present Neurourology and Urodynamics
2009-present Advances in Therapy
2009-present LUTS
Visiting professorships/invited lectures (since 2005; excluding company sponsored
symposia):
2005 German Society of Urology
2006 Asian Congress of Urology; British Pharmacological Society; German Society of
Nephrology; German Society of Urology; University of Halle, Germany; University of
Leipzig, Germany
2007 German Society of Urology; University of Bonn, Germany
2008 5th
International Receptor Symposium, Shizuoka, Japan;Controversies in Urology,
Barcelona, Spain; Forum Urodynamicum, Zürich, Switzerland; German Society of
Urology; University of Houston, TX, USA
2009 German Society of Urology¸Huyssens Hospital Essen, Germany; Japanese
Pharmacological Society; Korean Society of Experimental Urology; University of
Tennessee at Memphis, TN, USA
2010 University of Brescia, Italy; University of Cologne, Germany; University of
Groningen, Netherlands; University of Strasbourg, France
2011 European Association of Urology; Evidence-based Medicine Symposium, Athens,
Greece; German Society of Urology; King’s College London, UK
2012 Chinese Pharmacological Society; German Society of Urology; University of Bari,
Italy; University of Bonn, Germany; University of Hongkong, Hongkong; University
of Maastricht, Netherlands; University of Porto, Portugal
2013 German Society of Experimental and Clinical Pharmacology & Toxicology;
University of California at San Diego, CA, USA; University of Heidelberg, Mannheim
campus, Germany; University of Michigan at Ann Arbor, MI, USA
2014 9th
International Adrenoceptor Meeting; Global Congress on Lower Urinary Tract
Diseases symposium, Brussels, Belgium; Max-Delbrück Center, Berlin, Germany;
University of Duisburg-Essen, Essen campus, Germany; University of Giessen,
Germany; University of Groningen, Netherlands; Vlaams Instituut voor de
Biotechnologie, Belgium; World Congress of Pharmacology, Cape Town, South
Africa
2015 3rd
Pharmaceutical Medicine Symposium, Ingelheim, Germany; Australian Society for
Clinical and Experimental Pharmacology; Australasian Pharmaceutical Sciences
Association; Baker International Diabetes Institute, Melbourne, Australia; Monash
University, Melbourne, Australia; Physiological Society; Society of German Natural
Scientists and Physicians; University Frankfurt, Germany; University of Melbourne,
Australia; University of Westminster, London, UK
2016 4th
Pharmaceutical Medicine Symposium; European Heart Rhythm Association;
European Science Open Forum; European Society of Cardiology (Leadership and
Management in Cardiovascular Medicine Forum); Italian Physiological Society;
Medical University Hannover, Germany; Society of Urodynamics, Female Pelvic

5. Medicine & Urogenital Reconstruction; Technical University Munich, Germany;
Washington State University, Spokane, WA
Organization of scientific meetings
Member scientific committee International Continence Society, Cairo, Egypt, 20.-24.10.2008
Congress president 7th
International Meeting Sphingolipid Club, Leiden, Netherlands, 14.-
16.11.2008
Congress president 3rd
Symposium Pharmaceutical Medicine, Ingelheim, Germany, 30.-
31.1.2015
Member scientific committee 4th
Symposium Pharmaceutical Medicine, Berlin, Germany,
29.-30.1.2016
Teaching
Broad experience in the teaching of undergraduate students, medical students and graduate
students at five universities (University of California at San Diego, University of
Essen, Ruhr-University Bochum, University of Amsterdam, Johannes Gutenberg
University Mainz) in three different countries and educational systems (Germany,
USA, Netherlands)
Teaching-related research
Student and trainee supervision
20 Ph.D. students
50 Medical students for independent research projects (including German M.D. theses)
4 MSc and BSc students for independent research projects
12 Post-doctoral fellows and visiting scientists
2014-2016 mentor Edith Henschel-Meitner Mentoring Program, Johannes Gutenberg
University Medical School, Mainz, Germany
2015 mentor MDC-Mentoring Program, Max Delbrück Center for Molecular Medicine,
Berlin, Germany
Key publications (selected from >500, full list available upon request)
M. C. Michel, A. Rother, C. Hiemke, R. Ghraf (1987) Inhibition of synaptosomal high-affinity
uptake of dopamine and serotonin by estrogen agonists and antagonists. Biochem.
Pharmacol. 36: 3175-3180
M. C. Michel, A. Pingsmann, J. J. Beckeringh, H.-R. Zerkowski, N. Doetsch, O.-E. Brodde
(1988) Selective regulation of ß1- and ß2-adrenoceptors in the human heart by chronic
ß-adrenoceptor antagonist treatment. Br. J. Pharmacol. 94: 685-692
H. J. Motulsky, M. C. Michel (1988) Neuropeptide Y mobilizes Ca++
and inhibits adenylate
cyclase in human erythroleukemia cells. Am. J. Physiol. 255: E880-E885
M. C. Michel, A. Pingsmann, M. Nohlen, U. Siekmann, O.-E. Brodde (1989) Decreased
myometrial beta-adrenoceptors in women receiving beta-2-adrenergic tocolytic therapy:
correlation with lymphocyte beta-adrenoceptors. Clin. Pharmacol. Ther. 45: 1-8
M. C. Michel, L. F. Brass, A. Williams, G. M. Bokoch, V. J. LaMorte, H. J. Motulsky (1989)
α2-Adrenergic receptor stimulation mobilizes intracellular Ca++
in human
erythroleukemia cells. J. Biol. Chem. 264: 4986-4991
A. S. Maisel, P. Fowler, A. Rearden, H. J. Motulsky, M. C. Michel (1989) A new method for
isolation of human lymphocyte subsets reveals differential regulation of ß-adrenergic
receptors by terbutaline treatment. Clin. Pharmacol. Ther. 46: 429-439
M. C. Michel, P. A. Insel, O.-E. Brodde (1989) Are renal α-adrenergic receptor alterations a
cause of essential hypertension? FASEB J. 3: 139-144

6. M. C. Michel, J. W. Regan, M. A. Gerhardt, R. R. Neubig, P. A. Insel, H. J. Motulsky (1990)
Non-adrenergic [3
H]idazoxan binding sites are physically distinct from α2-adrenergic
receptors. Mol. Pharmacol. 37: 65-68
A. S. Maisel, K. U. Knowlton, P. Fowler, A. Rearden, M. G. Ziegler, H. J. Motulsky, P. A.
Insel, M. C. Michel (1990) Adrenergic control of circulating lymphocyte subpopula-
tions. Effects of congestive heart failure, dynamic exercise, and terbutaline treatment.
J. Clin. Invest. 85: 462-467
M. C. Michel, E. Schlicker, K. Fink, J. H. Boublik, M. Göthert, R. N. Willette, R. N. Daly, J.
P. Hieble, J. E. Rivier, H. J. Motulsky (1990) Distinction of NPY receptor subtypes in
vitro and in vivo. I. NPY18-36 discriminates between NPY receptor subtypes in vitro.
Am. J. Physiol. 259: E131-E139
N. A. Scott, M. C. Michel, J. H. Boublik, J. E. Rivier, S. Motomura, R. L. Crum, M. Landon,
M. R. Brown (1990) Distinction of NPY receptor subtypes in vitro and in vivo. II.
Differential hemodynamic effects of NPY and NPY18-36. Am. J. Physiol. 259: H174-
H180
A. S. Maisel, T. Harris, C. A. Rearden, M. C. Michel (1990) ß-Adrenergic receptors in
lymphocyte subsets after exercise. Alterations in normal individuals and patients with
congestive heart failure. Circulation 82: 2003-2010
M. C. Michel, S. Jäger, R. Casto, R. Rettig, C. Graf, M. Printz, P. A. Insel, T. Philipp, O.-E.
Brodde (1992) On the role of renal α-adrenergic receptors in spontaneously
hypertensive rats. Hypertension 19: 365-370
M. C. Michel, W. Gaida, A. G. Beck-Sickinger, H. A. Wieland, H. Doods, H. Dürr, G. Jung,
G. Schnorrenberg (1992) Further characterization of neuropeptide Y receptor subtypes
using centrally truncated analogs of neuropeptide Y: Evidence for subtype-
differentiating effects on affinity and intrinsic efficacy. Mol. Pharmacol. 42: 642-648
K. U. Knowlton, M. C. Michel, M. Itani, H.E. Shubeita, K. Ishihara, J. H. Brown, K. R. Chien
(1993) The α1A-adrenergic receptor subtype mediates biochemical, molecular, and
morphologic features of cultured myocardial cell hypertrophy. J. Biol. Chem. 268:
15374-15381
M. C. Michel, P. A. Insel (1994) Comparison of cloned and pharmacologically defined rat
tissue α1-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol. 350:
136-142
H. Chen, C. Fetscher, R. F. Schäfers, G. Wambach, T. Philipp, M. C. Michel (1996) Effects of
noradrenaline and neuropeptide Y on rat mesenteric microvessel contraction. Naunyn-
Schmiedeberg’s Arch. Pharmacol. 353: 314-323
W. Erdbrügger, J. Keffel, M. Knocks, T. Otto, T. Philipp, M. C. Michel (1997) Protein kinase
C isoenzymes in rat and human cardiovascular tissues.Br. J. Pharmacol. 120: 177-
186
K. Taguchi, M. Saitoh, S. Sato, M. Asano, M. C. Michel (1997) Effects of tamsulosin
metabolites at alpha-1 adrenoceptor subtypes. J. Pharmacol. Exp. Ther. 280: 1-5
A. Cavalli, A.-L. Lattion, E. Hummler, M. Nenniger, T. Pedrazzini, J.-F. Aubert, M. C.
Michel, M. Yang, G. Lembo, C. Vecchione, M. Mostardini, A. Schmidt, F. Beermann,
S. Cotecchia (1997) Decreased blood pressure response in mice deficient of the α1b-
adrenergic receptor. Proc. Natl. Acad. Sci. USA 94: 11589-11594
M. C. Michel, L. Mehlburger, H.-U. Bressel, H. Schumacher, R. F. Schäfers, M. Goepel
(1998) Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms:
does comorbidity alter tolerability? J. Urol. 160: 784-791
A. Alexandrov, S. Keffel, M. Goepel, M. C. Michel (1998) Stimulation of α1A-adrenoceptors
in Rat-1 cells inhibits extracellular signal-regulated kinase by activating p38 mitogen-
activated protein kinase. Mol. Pharmacol. 54: 755-760

7. M. C. Michel, A. Beck-Sickinger, H. Cox, H. N. Doods, H. Herzog, D. Larhammar, R.
Quirion, T. Schwartz, T. Westfall (1998) XVI. International Union of Pharmacology
recommendations for the nomenclature of neuropeptide Y, peptide YY and pancreatic
polypeptide receptors. Pharmacol. Rev. 50: 143-150
R. F. Schäfers, B. Fokuhl, A. Wasmuth, H. Schumacher, K. Taguchi, C. de Mey, T. Philipp,
M. C. Michel (1999) Differential vascular α1-adrenoceptor antagonism by tamsulosin
and terazosin. Br. J. Clin. Pharmacol. 47: 67-74
M. C. Michel, L. Mehlburger, H. Schumacher, H.-U. Bressel, M. Goepel (2000) Effect of
diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia.
J. Urol. 163: 1725-1729
G. Heusch, H. Post, M. C. Michel, M. Kelm, R. Schulz (2000) Endogenous nitric oxide and
myocardial adaptation to ischemia. Circ. Res. 87: 146-152
A. Bischoff, P. Czyborra, C. Fetscher, D. Meyer zu Heringdorf, K. H. Jakobs, M. C. Michel
(2000) Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and
mesenteric microvessels in vitro. Br. J. Pharmacol. 130: 1871-1877
A. Bischoff, P. Czyborra, D. Meyer zu Heringdorf, K. H. Jakobs, M. C. Michel (2000)
Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a
pertussis toxin-sensitive manner. Br. J. Pharmacol. 130: 1878-1883
C. Fetscher, M. Fleichman, M. Schmidt, S. Krege, M. C. Michel (2002) M3 muscarinic
receptors mediate contraction of human urinary bladder. Br. J. Pharmacol. 136: 641-
643
M. C. Michel, A. Bischoff, K. H. Jakobs (2002) Comparison of problem- and lecture-based
pharmacology teaching. Trends Pharmacol. Sci. 23: 168-170
M. U. Goebel, A. E. Trebst, J. Steiner, Y. F. Xie, M. S. Exton, S. Frede, A. E. Canbay, M. C.
Michel, U. Heemann, M. Schedlowski (2002) Behavioral conditioning of
immunosuppression is possible in humans. FASEB J. 16: 1869-1873
M. C. Michel, H. Bohner, J. Köster, R. Schäfers, U. Heemann (2004) Safety of telmisartan in
patients with arterial hypertension: an open-label, observational study. Drug Safety
27: 335-344
T. Schneider, C. Fetscher, S. Krege, M. C. Michel (2004) Signal transduction underlying
carbachol-induced contraction of human urinary bladder. J. Pharmacol. Exp. Ther.
309: 1148-1153
M. C. Michel, M. Oelke, M. Goepel, E. Beck, M. Burkart (2007) Relationships among
symptoms, bother, and treatment satisfaction in overactive bladder patients.
Neurourol. Urodyn. 26: 190-195
D. Rosskopf, M. C. Michel (2008) Pharmacogenomics of G protein-coupled receptor ligands
in cardiovascular medicine. Pharmacol. Rev. 60: 513-535
M. C. Michel, M. M. Barendrecht (2008) Physiological and pathological regulation of the
autonomic control of urinary bladder contractility. Pharmacol. Ther. 117: 297-312
W. Vrydag, A. E. Alewijnse, M. C. Michel (2009) Do gene polymorphisms alone or in
combination affect the function of human β3-adrenoceptors? Br. J. Pharmacol. 156:
127-134
M. C. Michel, T. Wieland, G. Tsujimoto (2009) How reliable are G-protein-coupled receptor
antibodies? Naunyn-Schmiedeberg’s Arch. Pharmacol. 379: 385-388
H. G. Ruhe, J. Booij, H. C. van Weert, J. B. Reitsma, E. J. F. Fransen, M. C. Michel, A. H.
Schene (2009) Evidence why paroxetine dose-escalation is not effective in major
depressive disorder: a randomized-controlled trial with assessment of serotonin
transporter occupancy. Neuropsychopharmacology 34: 999-1010
M. C. Michel, P. Radziszewski, C. Falconer, D. Marschall-Kehrel, K. Blot (2012) Unexpected
frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years.
Br. J. Clin. Pharmacol. 73: 821-825

8. E. H. Ohlstein, A. von Keitz, M. C. Michel (2012) A multicenter, double-blind, randomized,
placebo-controlled trial for the β3-adrenoceptor agonist solabegron for overactive
bladder. Eur. Urol. 62: 834-840
C. A. Teitsma, J. J. M. C. H. de la Rosette, M. C. Michel (2013) Are polymorphisms of the
3-adrenoceptor gene associated with an altered bladder function? Neurourol.
Urodyn. 32: 276-280
M. B. Michel-Reher, M. C. Michel (2013) Agonist-induced desensitization of human β3-
adrenoceptors expressed in human embryonic kidney cells. Naunyn-Schmiedeberg’s
Arch. Pharmacol. 386: 843-851
M. C. Michel, C. Foster, H. R. Brunner, L. Liu (2013) A systematic comparison of the
properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol.
Rev. 65: 809-848
M. C. Michel, R. Seifert, R. A. Bond (2014) Dynamic bias and its implications for drug
discovery. Nature Rev. Drug. Disc. 13: 869-870
M. C. Michel, C. Korstanje (2016) β3-Adrenoceptor agonists for overactive bladder
syndrome: role of translational pharmacology in a re-positioning drug development
project. Pharmacol. Ther. 159: 66-82
M. C. Michel, S. Gravas (2016) Safety and tolerability of β3-adrenoceptor agonists in the
treatment of overactive bladder syndrome – insight from transcriptosome and
experimental studies. Expert Opin. Drug Safety 15: 647-657
M. C. Michel, H. R. Brunner, C. Foster, Y. Huo (2016) Angiotensin II type 1 receptor
antagonists in animal models of vascular, cardiac, metabolic and renal disease.
Pharmacol. Ther. 164: 1-81